Header Logo

Connection

SETH LERNER to Antineoplastic Combined Chemotherapy Protocols

Back to Details
This is a "connection" page, showing publications SETH LERNER has written about Antineoplastic Combined Chemotherapy Protocols.
SETH LERNER
Connection Strength
1.719
Antineoplastic Combined Chemotherapy Protocols
  1. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. 2009 Jul-Aug; 27(4):391-9.
    View in: PubMed
    Score: 0.188
  2. Neoadjuvant chemotherapy for bladder cancer. Oncology (Williston Park). 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694.
    View in: PubMed
    Score: 0.182
  3. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. Expert Rev Anticancer Ther. 2006 Feb; 6(2):281-91.
    View in: PubMed
    Score: 0.160
  4. Bladder cancer clinical trials. Urol Oncol. 2005 Jul-Aug; 23(4):275-9.
    View in: PubMed
    Score: 0.154
  5. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
    View in: PubMed
    Score: 0.144
  6. Perioperative chemotherapy in locally advanced bladder cancer. Lancet. 2003 Jun 07; 361(9373):1922-3.
    View in: PubMed
    Score: 0.133
  7. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441.
    View in: PubMed
    Score: 0.113
  8. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep; 62(3):523-33.
    View in: PubMed
    Score: 0.062
  9. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
    View in: PubMed
    Score: 0.059
  10. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009 Sep 15; 115(18):4104-9.
    View in: PubMed
    Score: 0.051
  11. Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opin Pharmacother. 2008 Aug; 9(11):1885-93.
    View in: PubMed
    Score: 0.048
  12. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int. 2008 Jun; 101(11):1356-61.
    View in: PubMed
    Score: 0.047
  13. Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008 Apr; 101(8):937-43.
    View in: PubMed
    Score: 0.045
  14. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Gu?rin in Patients with Bacillus Calmette-Gu?rin-Unresponsive Non-Muscle Invasive Bladder Cancer. Eur Urol Oncol. 2025 Apr; 8(2):469-476.
    View in: PubMed
    Score: 0.037
  15. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20; 42(33):3911-3916.
    View in: PubMed
    Score: 0.036
  16. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104.
    View in: PubMed
    Score: 0.035
  17. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul; 18(21):2599-2614.
    View in: PubMed
    Score: 0.031
  18. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 01; 19(5):1414-20.
    View in: PubMed
    Score: 0.028
  19. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2000 Mar; 37(1-2):71-85.
    View in: PubMed
    Score: 0.027
  20. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15; 92(4):1165-71.
    View in: PubMed
    Score: 0.024
  21. The role of surgery in the management of pediatric pelvic rhabdomyosarcoma. J Urol. 1995 Aug; 154(2 Pt 1):540-5.
    View in: PubMed
    Score: 0.019
  22. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Jun; 9(6):943-5.
    View in: PubMed
    Score: 0.019
  23. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol. 2014 Nov; 32(8):1108-15.
    View in: PubMed
    Score: 0.018
  24. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993 Sep 15; 82(6):1695-700.
    View in: PubMed
    Score: 0.017
  25. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8.
    View in: PubMed
    Score: 0.016
  26. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther. 2009 Jul; 8(7):1772-8.
    View in: PubMed
    Score: 0.013
  27. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia. 2002 Apr; 16(4):632-5.
    View in: PubMed
    Score: 0.008
  28. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998 Oct 01; 129(7):559-66.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.